JP2013508295A - 薬物誘発性手足症候群を治療するための組成物および方法 - Google Patents

薬物誘発性手足症候群を治療するための組成物および方法 Download PDF

Info

Publication number
JP2013508295A
JP2013508295A JP2012534390A JP2012534390A JP2013508295A JP 2013508295 A JP2013508295 A JP 2013508295A JP 2012534390 A JP2012534390 A JP 2012534390A JP 2012534390 A JP2012534390 A JP 2012534390A JP 2013508295 A JP2013508295 A JP 2013508295A
Authority
JP
Japan
Prior art keywords
subject
ppe
phosphodiesterase inhibitor
drug toxicity
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012534390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508295A5 (2
Inventor
ハーウィッツ，ハーバート
Original Assignee
デューク・ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デューク・ユニヴァーシティ filed Critical デューク・ユニヴァーシティ
Publication of JP2013508295A publication Critical patent/JP2013508295A/ja
Publication of JP2013508295A5 publication Critical patent/JP2013508295A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012534390A 2009-10-16 2010-10-15 薬物誘発性手足症候群を治療するための組成物および方法 Pending JP2013508295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27909109P 2009-10-16 2009-10-16
US61/279,091 2009-10-16
PCT/US2010/052836 WO2011047256A1 (en) 2009-10-16 2010-10-15 Compositions and methods for the treatment of drug-induced hand-foot syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015246156A Division JP6063550B2 (ja) 2009-10-16 2015-12-17 薬物誘発性手足症候群を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2013508295A true JP2013508295A (ja) 2013-03-07
JP2013508295A5 JP2013508295A5 (2) 2013-12-05

Family

ID=43876575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534390A Pending JP2013508295A (ja) 2009-10-16 2010-10-15 薬物誘発性手足症候群を治療するための組成物および方法
JP2015246156A Active JP6063550B2 (ja) 2009-10-16 2015-12-17 薬物誘発性手足症候群を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015246156A Active JP6063550B2 (ja) 2009-10-16 2015-12-17 薬物誘発性手足症候群を治療するための組成物および方法

Country Status (6)

Country Link
US (2) US9220713B2 (2)
EP (1) EP2488642B1 (2)
JP (2) JP2013508295A (2)
CN (1) CN102648279B (2)
AU (1) AU2010306671B2 (2)
WO (1) WO2011047256A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528286A (ja) * 2017-08-18 2020-09-24 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 洗浄方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508295A (ja) * 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
CA2914815A1 (en) * 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
WO2016144230A1 (en) * 2015-03-06 2016-09-15 Telefonaktiebolaget Lm Ericsson (Publ) Method, network device, computer program and computer program product for mobile service chaining
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
KR102831159B1 (ko) 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US9004A (en) * 1852-06-08 Improvement in seed-planters
US9019A (en) * 1852-06-15 Charles fleischbl

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028237A1 (en) 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
US20090048179A1 (en) * 2005-02-22 2009-02-19 Cedars-Sinai Medical Center Use of 5-phosphodiesterase inhibitors to enhance the permeability of the blood-brain barrier of abnormal brain tissue and the blood-tumor barrier
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
WO2007138103A1 (en) 2006-06-01 2007-12-06 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP2246057A1 (en) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
JP2013508295A (ja) * 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US9004A (en) * 1852-06-08 Improvement in seed-planters
US9019A (en) * 1852-06-15 Charles fleischbl

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528286A (ja) * 2017-08-18 2020-09-24 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 洗浄方法

Also Published As

Publication number Publication date
AU2010306671A1 (en) 2012-05-10
WO2011047256A1 (en) 2011-04-21
JP6063550B2 (ja) 2017-01-18
US20120258970A1 (en) 2012-10-11
CN102648279B (zh) 2015-11-25
AU2010306671B2 (en) 2015-12-17
JP2016094450A (ja) 2016-05-26
US9220713B2 (en) 2015-12-29
EP2488642A1 (en) 2012-08-22
US20160074405A1 (en) 2016-03-17
US9629845B2 (en) 2017-04-25
EP2488642B1 (en) 2015-03-11
EP2488642A4 (en) 2013-03-06
CN102648279A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
JP6063550B2 (ja) 薬物誘発性手足症候群を治療するための組成物および方法
TWI757228B (zh) 含有槲皮素配糖體之筋萎縮抑制劑
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
JP2017503801A (ja) 小児における急性呼吸促迫症候群の治療のための吸入一酸化窒素ガスを使用する方法
JP2020055884A (ja) がんのためのグルフォスファミド組み合わせ療法
JP2020521797A5 (2)
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
Correale et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
CN111629718A (zh) 对癌症患者的治疗有用的尿碱剂
Kawahara et al. Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas
JPWO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
JP2011500650A5 (2)
Talalaev et al. Treatment with therapeutic plasma exchange in severe COVID-19 pneumonia: a case report and review of the literature
Zhao et al. Long-term administration of simvastatin reduces ventilator-induced lung injury and upregulates heme oxygenase 1 expression in a rat model
KR20200050761A (ko) 다이설피람을 포함하는 항암용 조성물
RU2724341C1 (ru) Комбинированная композиция для предупреждения или лечения рака, содержащая производные бензофенонтиазола в качестве vda и ингибитор топоизомеразы
Chen et al. Fatal pancreatitis occurred in a patient with refractory CD30+ anaplastic large cell lymphoma after brentuximab vedotin treatment
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
CN110876803B (zh) 一种包含乳蛋白和油酸的药物组合物
EP4452275A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
WO2023142996A1 (zh) 预防或治疗与抗肿瘤剂相关的疾病或病症的方法
JP2024531765A (ja) がん治療のための三剤療法
HK40029734A (en) Urine alkali agent useful for treatment of cancer patient

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150818